Cardiovascular diseases are the leading cause of death worldwide. Risk factors are rarely
seen individually, and the 2 most common and most frequently associated risk factors are …

Hypertension and dyslipidemia are two of the most commonly co-occurring cardiovascular
risk factors which together cause an increase in coronary heart disease-related events that …

Amlodipine/atorvastatin (Caduet®) is a once-daily fixed-dose combination of the
dihydropyridine calcium channel antagonist amlodipine and the HMG-CoA reductase …

This review describes the clinical profile and rationale for the development of a single-pill
formulation of the calcium channel blocker amlodipine besylate, a blood-pressure--lowering …

The aim was to evaluate the efficacy of a single-pill combination of atorvastatin/amlodipine
in patients with arterial hypertension, dyslipidemia and moderate to high cardiovascular risk …

In 2002, the World Health Organization estimated that over 58% of cardiovascular disease in
North America is due to 'both blood pressure and cholesterol higher than optimal' …

Guidelines stress the importance of the simultaneous management of multiple
cardiovascular risk factors. This can in part be achieved by coadministration of lipid …

The AVALON study was a randomized, multicenter trial to assess the efficacy and safety of
coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia …

Introduction: Hypertension (HTN) and dyslipemia (DYL) are two of the major modifiable
cardiovascular (CV) risk factors, determinants in the development of cerebrovascular and …

Single‐pill amlodipine besylate/atorvastatin calcium (Caduet®, Pfizer Inc, NY, USA) is the
first therapy aimed at the simultaneous treatment of hypertension (HTN) and dyslipidaemia …